Form 4: Syros Pharmaceuticals Director Sue Gail Eckhardt Reports Stock Option Grant and Stock Acquisition

Director Sue Gail Eckhardt reports acquisition of 4,000 shares of common stock and grant of stock options for 6,000 shares of Syros Pharmaceuticals.

Summary

• On June 5, 2024, Sue Gail Eckhardt, a director of Syros Pharmaceuticals, reported acquiring 4,000 shares of common stock at $0.00 per share.
• Following this transaction, Eckhardt directly owns 16,000 shares of common stock.
• Eckhardt was also granted a stock option to purchase 6,000 shares of common stock at an exercise price of $5.30 on June 5, 2024.
• The stock options expire on June 4, 2034.
• The option vests as to 50% of the shares six months from the grant date, with the remainder vesting monthly until the first anniversary, contingent on continued service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by a company director. The acquisition of shares and grant of options are mildly positive, indicating confidence, but it's not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.
• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing long-term value creation.

Future Outlook

The vesting schedule of the stock options is contingent on the director's continued service, suggesting a commitment to the company's long-term success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors and officers, regarding their holdings of the company's securities.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding the director's stake in the company.
• The vesting schedule of the stock options incentivizes the director to contribute to the company's long-term success, benefiting shareholders.

Key Dates

Keywords

Syros Pharmaceuticals, Director, Stock Option, Stock Acquisition, Form 4, Beneficial Ownership, Equity Securities